Evidence map›Paper›PMID 24229053›Full record

SynthesisBioscience reports2013

Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.

Maria Aparecida Azevedo Koike Folgueira, Simone Maistro, Maria Lucia Hirata Katayama, Rosimeire Aparecida Roela, Fiorita Gonzales Lopes Mundim, Suely Nanogaki, Geertruida H de Bock, M Mitzi Brentani

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Bioscience reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Cancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Maria Aparecida Azevedo Koike Folgueira*Departamento de Radiologia e Oncologia, Disciplina de Oncologia, Faculdade de Medicina da Universidade de São Paulo (LIM-24), São Paulo, Brasil.
Simone Maistro*Departamento de Radiologia e Oncologia, Disciplina de Oncologia, Faculdade de Medicina da Universidade de São Paulo (LIM-24), São Paulo, Brasil.
Maria Lucia Hirata Katayama*Departamento de Radiologia e Oncologia, Disciplina de Oncologia, Faculdade de Medicina da Universidade de São Paulo (LIM-24), São Paulo, Brasil.
Rosimeire Aparecida Roela*Departamento de Radiologia e Oncologia, Disciplina de Oncologia, Faculdade de Medicina da Universidade de São Paulo (LIM-24), São Paulo, Brasil.
Fiorita Gonzales Lopes Mundim§Departamento de Patologia, Universidade do Vale do Sapucaí, Pouso Alegre, MG, Brasil.
Suely Nanogaki‡Departamento de Anatomia Patológica, Hospital A.C. Camargo, São Paulo, Brasil.
Geertruida H de Bock†Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
M Mitzi Brentani*Departamento de Radiologia e Oncologia, Disciplina de Oncologia, Faculdade de Medicina da Universidade de São Paulo (LIM-24), São Paulo, Brasil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRAC Camargo Hospital · BRUniversidade do Vale do Sapucaí · BRUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CAFs (cancer-associated fibroblasts), the most abundant cell type in breast cancer stroma, produce a plethora of chemokines, growth factors and ECM (extracellular matrix) proteins, that may contribute to dissemination and metastasis. Axillary nodes are the first metastatic site in breast cancer; however, to the present date, there is no consensus of which specific proteins, synthesized by CAFs, might be related with lymph node involvement. The purpose of this study was to perform a systematic review of CAF biomarkers associated with the presence of regional metastasis. PubMed was searched using the words: 'breast cancer' and 'lymph node' and fibroblast or stroma or microenvironment. After exclusions, eight studies evaluating biomarkers immunoexpression in CAFs and lymph node status were selected. Biomarkers evaluated in these studies may be divided in two groups, according to their ontology: extracellular matrix components [MMP13 (matrix metalloproteinase 13), TIMP2 (tissue inhibitor of metalloproteinases-2), THBS1 (thrombospondin 1), LGALS1 (lectin, galactoside-binding, soluble, 1)] and response to wounding [PDPN (podoplanin), PLAU (plasminogen activator, urokinase), PLAUR (plasminogen activator, urokinase receptor), CAV1 (caveolin 1), THBS1, LGALS1]. A positive expression of MMP13 and LGALS1 in CAFs was associated with enhanced OR (odds ratio) for regional metastasis. Contrariwise, CAV1 positive staining of fibroblasts was associated with decreased OR for nodal involvement. Expression of MMP13, PDPN and CAV1 was further tested in a new series of 65 samples of invasive ductal breast carcinomas by immunohistochemistry and no association between biomarkers expression in CAFs and nodal status was found. It was suggested that breast cancer subtypes may differentially affect CAFs behaviour. It would be interesting to evaluate the prognostic significance of these biomarkers in CAFs from different tumour types.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleFibroblastsGalectin 1HumansLymphatic MetastasisMatrix Metalloproteinase 13Odds RatioStromal CellsBiomarkers, TumorGalectin 1LGALS1 protein, humanMatrix Metalloproteinase 13MMP13 protein, human

Identifiers

PMID24229053
PMCPMC3860578
OpenAlexW2020191309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.